Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone410-522-8707
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.33 million
Profitability
Miscellaneous
Employees64
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Cerecor (NASDAQ:CERC) Frequently Asked Questions
What is Cerecor's stock symbol?
Cerecor trades on the NASDAQ under the ticker symbol "CERC."
How were Cerecor's earnings last quarter?
Cerecor Inc (NASDAQ:CERC) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.03. The company had revenue of $4.45 million for the quarter, compared to analysts' expectations of $5.28 million. Cerecor had a negative return on equity of 143.30% and a negative net margin of 231.68%. View Cerecor's Earnings History.
When is Cerecor's next earnings date?
What price target have analysts set for CERC?
3 Wall Street analysts have issued twelve-month price targets for Cerecor's stock. Their predictions range from $8.00 to $11.00. On average, they anticipate Cerecor's stock price to reach $9.67 in the next twelve months. This suggests a possible upside of 179.4% from the stock's current price. View Analyst Price Targets for Cerecor.
What is the consensus analysts' recommendation for Cerecor?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerecor.
What are Wall Street analysts saying about Cerecor stock?
Here are some recent quotes from research analysts about Cerecor stock:
- 1. Maxim Group analysts commented, "Cerecor reported positive Parkinson’s disease (PD)- related neurogenic orthostatic hypotension (nOH). Key takeaways from the data include demonstration of a rapid and sustained improvement in systolic blood pressure upon standing particularly in the highest dose group (20mg); >7mmHg with max improvement of 29.1mmHg." (7/2/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We reiterate our Buy rating and $8 PT. Full data set is consistent with interim data." (7/2/2019)
- 3. HC Wainwright analysts commented, "We value Cerecor based on a discounted cash flow (DCF) approach that ascribes a total value of $530M to the company’s marketed product portfolio, neurology-focused assets and ultra-rare early-stage product candidate pipeline." (5/28/2019)
Has Cerecor been receiving favorable news coverage?
Media stories about CERC stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cerecor earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Cerecor.
Are investors shorting Cerecor?
Cerecor saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 784,300 shares, an increase of 5.2% from the August 30th total of 745,700 shares. Based on an average daily trading volume, of 75,300 shares, the short-interest ratio is presently 10.4 days. Currently, 2.3% of the company's stock are short sold. View Cerecor's Current Options Chain.
Who are some of Cerecor's key competitors?
Some companies that are related to Cerecor include Homology Medicines (FIXX), NextCure (NXTC), Arvinas (ARVN), DiaMedica Therapeutics (DMCAF), MacroGenics (MGNX), OrganiGram (OGI), Flexion Therapeutics (FLXN), Akero Therapeutics (AKRO), Akebia Therapeutics (AKBA), INDIVIOR PLC/S (INVVY), Achillion Pharmaceuticals (ACHN), TG Therapeutics (TGTX), Basilea Pharmaceutica (BPMUF), IGM Biosciences (IGMS) and Catalyst Pharmaceuticals (CPRX).
What other stocks do shareholders of Cerecor own?
Who are Cerecor's key executives?
Cerecor's management team includes the folowing people:
- Ms. Mariam E. Morris, Consultant (Age 51)
- Dr. Simon C. Pedder Ph.D., Exec. Chairman (Age 58)
- Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 45)
- Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)
- Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54)
How do I buy shares of Cerecor?
Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cerecor's stock price today?
One share of CERC stock can currently be purchased for approximately $3.46.
How big of a company is Cerecor?
What is Cerecor's official website?
How can I contact Cerecor?
Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected]
MarketBeat Community Rating for Cerecor (NASDAQ CERC)
MarketBeat's community ratings are surveys of what our community members think about Cerecor and other stocks. Vote "Outperform" if you believe CERC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERC will underperform the S&P 500 over the long term. You may vote once every thirty days.
